Coronavirus (COVID-19) Vaccine Update
Click here to learn more.
For information about COVID-19 or to view additional resources, please
Primary objective:To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma.
George Kim, MD